Cargando…
The combined efficacy of OTS964 and temozolomide for reducing the size of power-law coded heterogeneous glioma stem cell populations
Glioblastoma resists chemotherapy then recurs as a fatal space-occupying lesion. To improve the prognosis, the issues of chemoresistance and tumor size should be addressed. Glioma stem cell (GSC) populations, a heterogeneous power-law coded population in glioblastoma, are believed to be responsible...
Autores principales: | Sugimori, Michiya, Hayakawa, Yumiko, Tamura, Ryoi, Kuroda, Satoshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6481323/ https://www.ncbi.nlm.nih.gov/pubmed/31040930 http://dx.doi.org/10.18632/oncotarget.26800 |
Ejemplares similares
-
Targeting the T-Lak cell originated protein kinase by OTS964 shrinks the size of power-law coded heterogeneous glioma stem cell populations
por: Sugimori, Michiya, et al.
Publicado: (2017) -
Discovery of Power-Law Growth in the Self-Renewal of Heterogeneous Glioma Stem Cell Populations
por: Sugimori, Michiya, et al.
Publicado: (2015) -
OTS964, a TOPK Inhibitor, Is Susceptible to ABCG2-Mediated Drug Resistance
por: Yang, Yuqi, et al.
Publicado: (2021) -
PBK/TOPK inhibitor OTS964 resistance is mediated by ABCB1-dependent transport function in cancer: in vitro and in vivo study
por: Yang, Yuqi, et al.
Publicado: (2022) -
Cellular Heterogeneity and Cooperativity in Glioma Persister Cells Under Temozolomide Treatment
por: Rabé, Marion, et al.
Publicado: (2022)